Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?

Amy B. Heimberger; John H. Sampson

doi:10.1093/neuonc/noq169

Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?

Amy B. Heimberger, John H. Sampson

Research output: Contribution to journal › Review article › peer-review

82 Scopus citations

Abstract

With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.

Original language	English (US)
Pages (from-to)	3-13
Number of pages	11
Journal	Neuro-oncology
Volume	13
Issue number	1
DOIs	https://doi.org/10.1093/neuonc/noq169
State	Published - Jan 2011
Externally published	Yes

Keywords

Clinical trial
Glioblastoma multiforme
Immunotherapy
Malignant gliomas

ASJC Scopus subject areas

Clinical Neurology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/neuonc/noq169

Cite this

@article{bf02343d478a4b209586942049f90e37,

title = "Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?",

abstract = "With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.",

keywords = "Clinical trial, Glioblastoma multiforme, Immunotherapy, Malignant gliomas",

author = "Heimberger, {Amy B.} and Sampson, {John H.}",

year = "2011",

month = jan,

doi = "10.1093/neuonc/noq169",

language = "English (US)",

volume = "13",

pages = "3--13",

journal = "Neuro-oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Immunotherapy coming of age

T2 - What will it take to make it standard of care for glioblastoma?

AU - Heimberger, Amy B.

AU - Sampson, John H.

PY - 2011/1

Y1 - 2011/1

N2 - With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.

AB - With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.

KW - Clinical trial

KW - Glioblastoma multiforme

KW - Immunotherapy

KW - Malignant gliomas

UR - http://www.scopus.com/inward/record.url?scp=79951641692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951641692&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq169

DO - 10.1093/neuonc/noq169

M3 - Review article

C2 - 21149252

AN - SCOPUS:79951641692

SN - 1522-8517

VL - 13

SP - 3

EP - 13

JO - Neuro-oncology

JF - Neuro-oncology

IS - 1

ER -

Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this